Top Page
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
(6609)
Shanghai Heartcare Medical Technology Corp. Ltd. Class H (6609) vs. S&P 500 (SPY)
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Business Overview & Revenue Model
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Financial Statement Overview
| Breakdown | ||||
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 232.34M | 183.03M | 90.09M | 14.56M | 0.00 | Gross Profit |
| 163.76M | 124.33M | 54.95M | 7.09M | 0.00 | EBIT |
| -126.87M | -198.57M | -196.31M | -213.77M | -75.71M | EBITDA |
| -68.50M | -167.31M | -183.34M | -206.19M | -73.37M | Net Income Common Stockholders |
| -94.01M | -200.38M | -195.82M | -216.08M | -75.29M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 721.14M | 870.12M | 1.22B | 632.42M | 55.77M | Total Assets |
| 1.20B | 1.31B | 1.50B | 773.63M | 91.28M | Total Debt |
| 36.38M | 50.69M | 41.94M | 24.69M | 1.24M | Net Debt |
| -585.82M | -819.43M | -1.18B | -607.73M | -24.30M | Total Liabilities |
| 125.60M | 147.08M | 132.10M | 82.60M | 10.21M | Stockholders Equity |
| 1.08B | 1.17B | 1.37B | 681.37M | 81.07M |
| Cash Flow | Free Cash Flow | |||
| -137.72M | -304.01M | -260.33M | -90.42M | -53.11M | Operating Cash Flow |
| -88.41M | -266.77M | -205.85M | -74.81M | -32.29M | Investing Cash Flow |
| -125.45M | 44.84M | -161.10M | -4.53M | -45.29M | Financing Cash Flow |
| -21.48M | -24.75M | 821.25M | 686.22M | 94.50M |
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Technical Analysis
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $30.95B | 10.66 | 14.56% | 5.59% | -5.37% | 6.28% | |
74 Outperform | $27.18B | 12.17 | 8.95% | 3.50% | -3.09% | 0.67% | |
66 Neutral | $71.57B | 37.70 | 6.14% | 1.49% | 7.63% | -24.23% | |
56 Neutral | HK$61.70B | 267.34 | 0.42% | 0.53% | -2.06% | -83.44% | |
54 Neutral | HK$2.10B | 3.51 | 11.49% | ― | 47.32% | 492.76% | |
53 Neutral | HK$1.09B | ― | -1.28% | ― | 17.45% | 85.71% | |
52 Neutral | $5.04B | 3.15 | -44.58% | 2.85% | 16.08% | -0.27% |
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Corporate Events
Shanghai Heartcare Medical Technology Corp. Ltd. has announced an Extraordinary General Meeting (EGM) to be held on May 26, 2025, to discuss and potentially approve the 2025 H Share Incentive Scheme and related resolutions. This initiative is aimed at enhancing shareholder value and aligning the interests of the company’s management with those of its shareholders, potentially impacting its market positioning and stakeholder engagement.
Shanghai HeartCare Medical Technology Corporation Limited has announced a proposal to adopt the 2025 H Share Incentive Scheme. The scheme aims to attract and retain key participants, align their interests with the company’s goals, and enhance long-term performance. The adoption of the scheme is subject to shareholder approval at an upcoming extraordinary general meeting, and it is expected to positively impact the company’s operational and strategic objectives.
Shanghai HeartCare Medical Technology Corporation Limited has announced the closure of its H Share register of members from April 26, 2025, to May 26, 2025, to facilitate its upcoming extraordinary general meeting (EGM) scheduled for May 26, 2025. This closure is aimed at determining the list of shareholders eligible to attend and vote at the EGM, which follows the annual general meeting on the same day. The move is significant for stakeholders as it outlines the procedural steps for shareholder participation and voting, ensuring transparency and orderly conduct of corporate governance.
Shanghai Heartcare Medical Technology Corp. Ltd. has announced its 2024 Annual General Meeting (AGM) scheduled for May 26, 2025. During the AGM, the company will consider and approve various resolutions, including the work reports of the board and supervisory committee, profit distribution plan, audited financial statements, and the re-appointment of auditors. Additionally, a special resolution will be discussed to authorize the issuance of additional shares, granting the board a general mandate to manage such issuances. These resolutions are pivotal for the company’s strategic planning and financial management, potentially impacting its market position and shareholder value.
Shanghai HeartCare Medical Technology Corporation Limited has established a nomination committee within its board of directors to enhance corporate governance and standardize the nomination procedures for directors and senior management. This committee is responsible for preparing selection procedures, conducting initial reviews of candidates, and providing recommendations to the board, thereby potentially impacting the company’s operational efficiency and governance structure.
In 2024, Shanghai Heartcare Medical Technology Corp. Ltd. reported a 19.6% increase in revenue to RMB277.9 million, despite a decrease in gross profit margin due to competitive pricing pressures. The company’s loss before tax significantly decreased by 88.3%, attributed to cost control and efficiency measures. The company is focusing on the development and sales of neuro-intervention devices, with notable increases in sales volumes for stroke treatment devices. It has also achieved regulatory approvals for new products and is expanding its international market reach with multiple product registrations and certifications.
Shanghai Heartcare Medical Technology Corp. Ltd. announced significant changes in its board and supervisory committee to enhance corporate governance and meet new gender diversity requirements. These changes include the appointment of Ms. Zhang Kun to the Nomination Committee and Mr. Liu Baiwei as the new Employee Representative Supervisor, replacing Mr. Xue Zongyu, who resigned due to personal commitments.
Shanghai Heartcare Medical Technology Corp. Ltd. has announced the composition of its board of directors and the roles within its four key committees. This organizational update is crucial for stakeholders as it outlines the leadership structure, which can impact the company’s strategic direction and governance.
Shanghai HeartCare Medical Technology Corporation Limited has announced that its board of directors will meet on March 27, 2025, to consider and approve the annual results for the year ended December 31, 2024. The meeting will also address the potential recommendation for a final dividend payment. This announcement indicates the company’s ongoing commitment to transparency and shareholder engagement, potentially impacting its financial outlook and investor relations.